Oral Losartan in Prevention of Post-ERCP Paancreatitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
Oral losartan given in the dose of 50 mg one hour before ERCP was studied in the prevention of post ERCP pancreatitis in 50 patients indicated for ERCP in comparison with another 50 patients underwent ERCP without receiving oral losartan.
Epistemonikos ID: 95fb6ece4edd10ab96db7b72c9ef6bcdb8369ac5
First added on: May 22, 2024